EcoDrugPlus

Arachidonate 12-Lipoxygenase

Ensembl ID : ENSDARG00000069463
Gene Symbol: ALOX12
20 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase B, Tandem Duplicate 1

Ensembl ID : ENSDARG00000043085
Gene Symbol: ALOX5B.1
5 Cross references
146 Possible Orthologues:

Arachidonate 5-Lipoxygenase B, Tandem Duplicate 2

Ensembl ID : ENSDARG00000043089
Gene Symbol: ALOX5B.2
5 Cross references
146 Possible Orthologues:

Arachidonate 5-Lipoxygenase B, Tandem Duplicate 3

Ensembl ID : ENSDARG00000069966
Gene Symbol: ALOX5B.3
5 Cross references
146 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein

Ensembl ID : ENSDARG00000054755
Gene Symbol: ALOX5AP
8 Enzyme and pathways 5 Cross references
201 Possible Orthologues:

Arginine Vasopressin Receptor 1aa

Ensembl ID : ENSDARG00000077083
Gene Symbol: AVPR1AA
8 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Arginine Vasopressin Receptor 1ab

Ensembl ID : ENSDARG00000045788
Gene Symbol: AVPR1AB
8 Enzyme and pathways 5 Cross references
196 Possible Orthologues:

Arginine Vasopressin Receptor 2a, Duplicate A

Ensembl ID : ENSDARG00000007436
Gene Symbol: AVPR2AA
5 Cross references
197 Possible Orthologues:

Arginine Vasopressin Receptor 2a, Duplicate B

Ensembl ID : ENSDARG00000029219
Gene Symbol: AVPR2AB
15 Enzyme and pathways 5 Cross references
197 Possible Orthologues:

Aryl Hydrocarbon Receptor 1a

Ensembl ID : ENSDARG00000020046
Gene Symbol: AHR1A
5 Cross references
155 Possible Orthologues:

Aurora Kinase A

Ensembl ID : ENSDARG00000012485
Gene Symbol: AURKA
19 Enzyme and pathways 5 Cross references
233 Possible Orthologues:

Aurora Kinase B

Ensembl ID : ENSDARG00000037640
Gene Symbol: AURKB
30 Enzyme and pathways 5 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).